| CAS NO: | 258279-04-8 |
| 包装 | 价格(元) |
| 500ug | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| Physical Appearance | A crystalline solid |
| Storage | Desiccate at -20°C |
| M.Wt | 3370.9 |
| Cas No. | 258279-04-8 |
| Formula | C149H249N47O42 |
| Solubility | Soluble in H2O |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
饥饿素(Ghrelin)是GHS受体的特异性内源配体,可剂量依耐性地刺激体内外循环生长激素(GH)水平的显著提高.人酰基化ghrelin是可以跨越血脑屏障的主要活性形式,以具有比GHSR拮抗剂(D-Lys3)-GHRP-6 (IC50, 0.9×10-6M)更强的亲和力(IC50, 0.3×10-9M)影响急性神经元的活性[1].
Ghrelin有激发食欲\增加生长激素分泌和低分解代谢\提高胃肠蠕动\增加心输出量\提高肺功能及抗炎的作用.
Ghrelin在全胃切除术\食管切除术及新辅助化疗的临床应用可刺激食物摄取\提高生活质量评分及将不良反应最小化.最近,ghrelin是神经性厌食[2]\恶病质[3]\BW[4]及食欲不振[5]\全身炎症反应[6]及癌症[7]的有效管理方式.总之,ghrelin是一种有前景的治疗分解代谢状态和增强恶病质或获得性免疫缺陷综合征中的免疫功能的候选药物,同时也是治疗饮食失调(如肥胖症和神经性厌食)的候选药物.
参考文献：
1. M. Traebert,* T. Riediger, S. Whitebread,* E. Scharrer and H. A. Schmid*. Ghrelin Acts on Leptin-Responsive Neurones in the Rat Arcuate Nucleus. Journal of Neuroendocrinology, 2002, Vol. 14, 580–586
2. Hotta M, Ohwada R, Akamizu T, Shibasaki T, Takano K, Kangawa K. Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. Endocr J. 2009;56:1119–28.
3. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005;128:1187–93.
4. Adachi S, Takiguchi S, Okada K, Yamamoto K, Yamasaki M, Miyata H, et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology. 2010;138:1312–20.
5. Hiura Y, Takiguchi S, Yamamoto K, Kurokawa Y, Yamasaki M, Nakajima K, et al. Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients. Int J Clin Oncol. 2012;17:316–23.
6. Cheyuo C, Jacob A, Wang P. Ghrelin-mediated sympathoinhibition and suppression of inflammation in sepsis. Am J Physiol Endocrinol Metab. 2012;302:E265–72.
7. Yoshida N, Watanabe M, Baba Y, Iwagami S, Ishimoto T, Iwatsuki M, et al. Risk factors for pulmonary complications after esophagectomy for esophageal cancer. Surg Today. 2014;44:526–32.
m.cnreagent.com